Benzinga | Dec 20, 2021 09:21AM EST

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $59

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $55 to $59.